Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Pre Symptomatic COVID Screening

Technical Report ·
DOI:https://doi.org/10.2172/1673817· OSTI ID:1673817
 [1];  [1];  [1]
  1. Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)
Temperature checks for fever are extensively used for preliminary COVID screenings but are ineffective during the incubation stage of infection when a person is asymptotic. Researchers at the European Centre for Disease Prevention and Control concluded that approximately 75% of passengers infected with COVID-19 and traveling from affected Chinese cities would not be detected by early screening. Core body temperature is normally kept within a narrow range and has the smallest relative standard deviation of all vital signs. Heat in the body is prioritized around internal organs at the expense of the periphery by controlling blood flow. In fact, blood flow to the skin may vary by a factor of 100 depending on thermal conditions. This adaptation causes rapid temperature fluctuations in different skin regions from changes in cardiac output, metabolism, and likely cytokine diffusion during inflammation that would not be seen in average core body temperature. Current IR and thermal scanners used for temperature checks are not necessarily reflective of core body temperatures and require cautious interpretation as they frequently result in false positive and false negative diagnosis. Hand held thermometers measure average skin temperatures and can get readings that differ from core body temperature by as much as 7°. Rather than focusing on a core body temperature threshold assessment we believe that variability of temperature patterns using a novel wearable transdermal microneedle sensor will be more sensitive to infections in the incubation stage and propose to develop a wearable transdermal temperature sensor using established Sandia microneedle technology for pre symptomatic COVID screening that can additionally be used to monitor disease progression at later stages.
Research Organization:
Sandia National Laboratories (SNL-NM), Albuquerque, NM (United States)
Sponsoring Organization:
USDOE National Nuclear Security Administration (NNSA)
DOE Contract Number:
AC04-94AL85000; NA0003525
OSTI ID:
1673817
Report Number(s):
SAND-2020-10359; 691383
Country of Publication:
United States
Language:
English

Similar Records

Pre-Symptomatic COVID Screening
Technical Report · Tue Sep 01 00:00:00 EDT 2020 · OSTI ID:1670887

Electrochemical aptamer-based sensors: leveraging the sensing platform for minimally-invasive microneedle measurements and fundamental exploration of sensor biofouling dynamics
Technical Report · Sun Oct 01 00:00:00 EDT 2023 · OSTI ID:2430147